Australia Health

Australian antiviral developer Island Pharmaceuticals (ASX:ILA) has been granted US Patent Number 12,508,266 by the US Patent and Trademark Office for the use of Galidesivir.

Neuren Pharmaceuticals (ASX:NEU) announced that results from its Phase 2 clinical trial of NNZ-2591 in children and adolescents with Phelan-McDermid syndrome have been published in Neurology Genetics

UC San Diego Health has commenced clinical use of 4DMedical’s (ASX:4DX) advanced respiratory imaging technology, CT:VQ.

Nexsen (ASX:NXN) has taken a major step toward US market entry with the commencement of engagement with the US Food and Drug Administration for its rapid Group B Streptococcus point-of-care diagnostic.

Australian antiviral developer Island Pharmaceuticals (ASX: ILA) has provided an update on its ongoing engagement with the US Food and Drug Administration regarding the clinical development of Galidesivir.

Biome Australia (ASX:BIO) reported record sales for the second quarter and first half of FY26, delivering continued strong growth despite seasonal headwinds.

Imugene (ASX:IMU), a clinical-stage immuno-oncology company, announced that Dr. Bradley Glover has resigned from his role as COO to focus on other business interests.

Dual-listed biotech Mesoblast (ASX:MSB) has announced that chair Jane Bell will retire from the role and continue as a non-executive director.

4DMedical (ASX:4DX), a leader in respiratory imaging technology, has appointed Julian Sutton as CFO and executive director.

AdAlta (ASX:1AD) and its cellular immunotherapy subsidiary, AdCella, have announced a major global collaboration with Shanghai Cell Therapy Group to co-develop the first-in-class CAR-T therapy, BZDS1901, for markets outside Greater China.

Neurizon Therapeutics (ASX:NUZ) provided an update on its lead investigational therapy for Amyotrophic Lateral Sclerosis, NUZ-001.

Arovella Therapeutics (ASX:ALA) has filed an Investigational New Drug application with the US Food and Drug Administration for ALA-10.